---
title: "Five-Year Trajectory of Autonomic Symptoms in Biologically Confirmed Parkinson's Disease"
id: "medrxiv-23-longitudinal-investigation-of-autonomic-symptoms-in-biologically-confirmed-saa"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-23-longitudinal-investigation-of-autonomic-symptoms-in-biologically-confirmed-saa"
content_type: "clinical_feed_article"
specialty: "Neurology"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.11.09.26367184v1?rss=1"
published_at: "2026-11-09T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Five-Year Trajectory of Autonomic Symptoms in Biologically Confirmed Parkinson's Disease
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-23-longitudinal-investigation-of-autonomic-symptoms-in-biologically-confirmed-saa
- **Specialty:** [Neurology](https://medichelpline.com/clinical-feed/neurology.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.11.09.26367184v1?rss=1)
- **Published At:** 2026-11-09T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- Investigators analyzed autonomic symptom progression over five years in **Parkinson's disease** using data from the Parkinson Progression Markers Initiative (**PPMI**). - The cohort comprised 874 PD participants and 252 healthy controls (HC) with annual **SCOPA-AUT** assessments. - Autonomic involvement defined as domain subscore >1 on **SCOPA-AUT**; gastrointestinal and urinary domains were the most common at baseline. - At baseline, 71% of PD participants reported >1 affected autonomic domain; among 287 PD participants with five-year follow-up, that proportion rose to 85%. - Healthy controls reporting >1 affected autonomic domain increased from 40% at baseline to 46% among 145 with five-year follow-up. - The study team observed increasing use of medications for constipation and urinary dysfunction over time in PD. - Cardiovascular comorbidities were common in both groups and increased in prevalence during follow-up. - Greater baseline autonomic symptom burden predicted more rapid cognitive decline in PD (p=0.002) but did not predict faster motor decline; authors noted this cognitive effect was driven by participants with severe autonomic symptoms. - Analyses used generalized estimating equations, adjusted for age, sex, medication, and comorbidities. - The source is a preprint; investigators performed a secondary analysis of de-identified PPMI data and limited longitudinal analyses to participants with at least one annual follow-up.
## Clinical Analysis & Structured Key Points
[](https://www.medrxiv.org/cdn-cgi/content?id=.n0s.4_qvNpLeNEhRsp2.AP2h5r2qObY27zSboYXT7E-1794265750.878157-1.2.1.1-oDrlZ65DskudgNPWgus1gLDkQp0NWSo5EbyR4cFkL4pstRFMAwX.MOqAJvil45tB) [Skip to main content](https://www.medrxiv.org/content/10.64898/2026.11.09.26367184v1?rss=1#main-content) [![medRxiv](https://www.medrxiv.org/sites/default/files/medrxiv_inner_logo.png)](https://www.medrxiv.org/) * [Home](https://www.medrxiv.org/) * [Submit](https://www.medrxiv.org/submit-a-manuscript) * [FAQ](https://www.medrxiv.org/about/FAQ) * [Blog](https://connect.medrxiv.org/news/) * [ALERTS / RSS](https://www.medrxiv.org/content/alertsrss) * [Resources](https://connect.medrxiv.org/resources/) * [About](https://www.medrxiv.org/content/about-medrxiv) Search for this keyword [Advanced Search](https://www.medrxiv.org/search) Follow this preprint # Longitudinal Investigation of Autonomic Symptoms in Biologically Confirmed (SAA+) Parkinson's Disease Adeel Ali Memon, Seung Ho Choi, Jie Yin, David-Erick Lafontant, Chelsea Caspell-Garcia, Daniel Weintraub, Amy W. Amara, Marina Picillo doi: https://doi.org/10.64898/2026.11.09.26367184 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Adeel Ali Memon 1 University of Vermont, Larner College of Medicine; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Adeel%2BAli%2BMemon%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Memon%20AA&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AAdeel%2BAli%2BMemon%2B) Seung Ho Choi 2 Department of Biostatistics, College of Public Health, University of Iowa; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Seung%2BHo%2BChoi%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Choi%20SH&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ASeung%2BHo%2BChoi%2B) Jie Yin 2 Department of Biostatistics, College of Public Health, University of Iowa; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Jie%2BYin%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Yin%20J&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AJie%2BYin%2B) David-Erick Lafontant 2 Department of Biostatistics, College of Public Health, University of Iowa; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=David-Erick%2BLafontant%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Lafontant%20D&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ADavid-Erick%2BLafontant%2B) Chelsea Caspell-Garcia 2 Department of Biostatistics, College of Public Health, University of Iowa; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Chelsea%2BCaspell-Garcia%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Caspell-Garcia%20C&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AChelsea%2BCaspell-Garcia%2B) Daniel Weintraub 3 Department of Psychiatry, Perelman School of Medicine at the University of Pennsylvania,; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Daniel%2BWeintraub%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Weintraub%20D&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ADaniel%2BWeintraub%2B) Amy W. Amara 4 Department of Neurology, University of Colorado, Anschutz Medical Campus; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Amy%2BW.%2BAmara%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Amara%20AW&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AAmy%2BW.%2BAmara%2B) * For correspondence: amy.amara@cuanschutz.edu Marina Picillo 5 Department of Medicine, Surgery and Dentistry Scuola Medica Salernitana, University of Salerno * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Marina%2BPicillo%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Picillo%20M&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AMarina%2BPicillo%2B) * [Abstract](https://www.medrxiv.org/content/10.64898/2026.11.09.26367184v1)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_art/node:1340571/1) * [Info/History](https://www.medrxiv.org/content/10.64898/2026.11.09.26367184v1.article-info)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_info/node:1340571/1) * [Metrics](https://www.medrxiv.org/content/10.64898/2026.11.09.26367184v1.article-metrics)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_metrics/node:1340571/1) * [Data/Code](https://www.medrxiv.org/content/10.64898/2026.11.09.26367184v1.external-links)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_data_code/node:1340571/1) * [ Preview PDF](https://www.medrxiv.org/content/10.64898/2026.11.09.26367184v1.full.pdf+html)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_pdf/node:1340571/1) ![Loading](https://www.medrxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif) ## Abstract Background Autonomic symptoms are common in Parkinson disease (PD) and impact quality of life, with unclear relationship to motor and cognitive progression. Objective: Characterize five-year progression of autonomic symptoms in early PD and their association with motor and cognitive outcomes. Methods We analyzed data from 874 PD participants and 252 healthy controls (HC) enrolled in Parkinson Progression Markers Initiative (PPMI). Autonomic symptoms were assessed annually over five years using Scales for Outcomes in Parkinson's disease-Autonomic dysfunction (SCOPA-AUT); affected autonomic domains were defined as domain subscore >1. Clinical measures included MDS-UPDRS and Montreal Cognitive Assessment. Generalized estimating equations evaluated longitudinal changes, adjusting for age, sex, medication, and comorbidities. Results: At baseline, 71% of PD participants reported >1 affected autonomic domain, increasing to 85% among 287 PD participants with 5-year follow-up; HCs reporting >1 affected autonomic domain increased from 40% of participants at baseline to 46% among 145 participants with 5-year follow-up. Gastrointestinal and urinary symptoms were most prevalent in PD. Medication use for constipation and urinary dysfunction increased over time in PD. Cardiovascular comorbidities were common and increased in prevalence in both groups. Greater baseline autonomic symptom burden predicted more rapid cognitive, but not motor decline in PD (p=0.002). Conclusion: Autonomic symptoms in PD are common at disease onset, near universal after 5 years, and associated with faster cognitive, but not motor, decline, driven by those with severe symptoms. The high prevalence and impact of autonomic symptoms in early PD highlights the importance of early assessment and management of these symptoms. ### Competing Interest Statement PPMI a public-private partnership is funded by the Michael J. Fox Foundation for Parkinson Research and funding partners, including 4D Pharma, Abbvie, AcureX, Allergan, Amathus Therapeutics, Aligning Science Across Parkinson's, AskBio, Avid Radiopharmaceuticals, BIAL, BioArctic, Biogen, Biohaven, BioLegend, BlueRock Therapeutics, Bristol-Myers Squibb, Calico Labs, Capsida Biotherapeutics, Celgene, Cerevel Therapeutics, Coave Therapeutics, DaCapo Brainscience, Denali, Edmond J. Safra Foundation, Eli Lilly, Gain Therapeutics, GE HealthCare, Genentech, GSK, Golub Capital, Handl Therapeutics, Insitro, Jazz Pharmaceuticals, Johnson & Johnson Innovative Medicine, Lundbeck, Merck, Meso Scale Discovery, Mission Therapeutics, Neurocrine Biosciences, Neuron23, Neuropore, Pfizer, Piramal, Prevail Therapeutics, Roche, Sanofi, Servier, Sun Pharma Advanced Research Company, Takeda, Teva, UCB, Vanqua Bio, Verily, Voyager v. 25MAR2024 Therapeutics, the Weston Family Foundation and Yumanity Therapeutics. ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: Our analysis included PPMI participants with autonomic function data up to five years of follow-up. Longitudinal analyses were limited to participants with at least one annual follow-up due to adjustment for baseline response. This secondary analysis of de-identified PPMI data was conducted following PPMI data usage guidelines and did not require further ethical review. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes ## Data Availability Data used in the preparation of this article were obtained on January 8, 2024 from the Parkinson Progression Markers Initiative (PPMI) database (www.ppmi-info.org/access-data-specimens/download-data), RRID:SCR_006431. For up-to-date information on the study, visit www.ppmi-info.org. This analysis was conducted by the PPMI Statistics Core and used actual dates of activity for participants, a restricted data element not available to public users of PPMI data. Statistical analysis codes used to perform the analyses in this article are shared on Zenodo (https://doi.org/10.5281/zenodo.15739155). Copyright [ The copyright holder has placed this preprint in the Public Domain.](https://creativecommons.org/publicdomain/zero/1.0/) It is no longer restricted by copyright. Anyone can legally share, reuse, remix, or adapt this material for any purpose without crediting the original authors. bioRxiv and medRxiv thank the following for their generous financial support: > The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, The University of Edinburgh, University of Washington, and Vrije Universiteit Amsterdam. [Donate to openRxiv ](https://www.zeffy.com/en-US/donation-form/donate-to-make-a-difference-10981) [ Back to top](https://www.medrxiv.org/content/10.64898/2026.11.09.26367184v1?rss=1#page) [ Previous](https://www.medrxiv.org/content/10.64898/2026.11.06.26367456v1 "OPEN: A Community-Informed Metadata Framework for Interoperable Computable Phenotypes")[Next ](https://www.medrxiv.org/content/10.64898/2026.11.06.26367430v1 "Stakeholder perspectives and preferences for long-acting injectables for tuberculosis treatment and prevention: a multi-regional mixed-methods study") Posted November 09, 2026. [ Download PDF](https://www.medrxiv.org/content/10.64898/2026.11.09.26367184v1.full.pdf) Print/Save Options [Download PDF](https://www.medrxiv.org/content/medrxiv/early/2026/11/09/2026.11.09.26367184.full.pdf)Full Text & In-line FiguresXML [More Info](https://www.medrxiv.org/about/FAQ#PrintOptions "More Information on Print/Save Options") [ Author Declarations](https://www.medrxiv.org/content/10.64898/2026.11.09.26367184v1#p-5) [ Data/Code](https://www.medrxiv.org/content/early/2026/11/09/2026.11.09.26367184.external-links) [ Email](https://www.medrxiv.org/ "Email this Article") [ Share](https://www.medrxiv.org/) Longitudinal Investigation of Autonomic Symptoms in Biologically Confirmed (SAA+) Parkinson's Disease Adeel Ali Memon, Seung Ho Choi, Jie Yin, David-Erick Lafontant, Chelsea Caspell-Garcia, Daniel Weintraub, Amy W. Amara, Marina Picillo medRxiv 2026.11.09.26367184; doi: https://doi.org/10.64898/2026.11.09.26367184 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Share This Article: Copy [![Twitter logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/twitter.png)](https://www.medrxiv.org/highwire_log/share/twitter?link=http%3A%2F%2Ftwitter.com%2Fshare%3Furl%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.11.09.26367184v1%26text%3DLongitudinal%2520Investigation%2520of%2520Autonomic%2520Symptoms%2520in%2520Biologically%2520Confirmed%2520%2528SAA%252B%2529%2520Parkinson%2527s%2520Disease "Share this on Twitter") [![Facebook logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/fb-blue.png)](https://www.medrxiv.org/highwire_log/share/facebook?link=http%3A%2F%2Fwww.facebook.com%2Fsharer.php%3Fu%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.11.09.26367184v1%26t%3DLongitudinal%2520Investigation%2520of%2520Autonomic%2520Symptoms%2520in%2520Biologically%2520Confirmed%2520%2528SAA%252B%2529%2520Parkinson%2527s%2520Disease "Share on Facebook") [![LinkedIn logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/linkedin-32px.png)](https://www.medrxiv.org/highwire_log/share/linkedin?link=http%3A%2F%2Fwww.linkedin.com%2FshareArticle%3Fmini%3Dtrue%26url%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.11.09.26367184v1%26title%3DLongitudinal%2520Investigation%2520of%2520Autonomic%2520Symptoms%2520in%2520Biologically%2520Confirmed%2520%2528SAA%252B%2529%2520Parkinson%2527s%2520Disease%26summary%3D%26source%3DmedRxiv "Publish this post to LinkedIn") [![Mendeley logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/mendeley.png)](https://www.medrxiv.org/highwire_log/share/mendeley?link=http%3A%2F%2Fwww.mendeley.com%2Fimport%2F%3Furl%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.11.09.26367184v1%26title%3DLongitudinal%2520Investigation%2520of%2520Autonomic%2520Symptoms%2520in%2520Biologically%2520Confirmed%2520%2528SAA%252B%2529%2520Parkinson%2527s%2520Disease "Share on Mendeley") [ Citation Tools](https://www.medrxiv.org/ "Citation Tools") Reviews and Context 0 Comment 0 TRIP Peer Reviews 0 Community Reviews 0 Automated Services 0 Blogs/Media 0 Author Videos **Subject Areas** [**All Articles**](https://www.medrxiv.org/content/early/recent) * [Addiction Medicine](https://www.medrxiv.org/collection/addiction-medicine) (638) * [Allergy and Immunology](https://www.medrxiv.org/collection/allergy-and-immunology) (918) * [Anesthesia](https://www.medrxiv.org/collection/anesthesia) (351) * [Cardiovascular Medicine](https://www.medrxiv.org/collection/cardiovascular-medicine) (5008) * [Dentistry and Oral Medicine](https://www.medrxiv.org/collection/dentistry-and-oral-medicine) (496) * [Dermatology](https://www.medrxiv.org/collection/dermatology) (428) * [Emergency Medicine](https://www.medrxiv.org/collection/emergency-medicine) (676) * [Endocrinology (including Diabetes Mellitus and Metabolic Disease)](https://www.medrxiv.org/collection/endocrinology-including-diabetes-mellitus-and-metabolic-disease) (1694) * [Epidemiology](https://www.medrxiv.org/collection/epidemiology) (16268) * [Forensic Medicine](https://www.medrxiv.org/collection/forensic-medicine) (36) * [Gastroenterology](https://www.medrxiv.org/collection/gastroenterology) (1241) * [Genetic and Genomic Medicine](https://www.medrxiv.org/collection/genetic-and-genomic-medicine) (7283) * [Geriatric Medicine](https://www.medrxiv.org/collection/geriatric-medicine) (751) * [Health Economics](https://www.medrxiv.org/collection/health-economics) (1093) * [Health Informatics](https://www.medrxiv.org/collection/health-informatics) (5293) * [Health Policy](https://www.medrxiv.org/collection/health-policy) (1468) * [Health Systems and Quality Improvement](https://www.medrxiv.org/collection/health-systems-and-quality-improvement) (1833) * [Hematology](https://www.medrxiv.org/collection/hematology) (599) * [HIV/AIDS](https://www.medrxiv.org/collection/hiv-aids) (1382) * [Infectious Diseases (except HIV/AIDS)](https://www.medrxiv.org/collection/infectious_diseases) (16492) * [Intensive Care and Critical Care Medicine](https://www.medrxiv.org/collection/intensive-care-and-critical-care-medicine) (1203) * [Medical Education](https://www.medrxiv.org/collection/medical-education) (700) * [Medical Ethics](https://www.medrxiv.org/collection/medical-ethics) (156) * [Nephrology](https://www.medrxiv.org/collection/nephrology) (752) * [Neurology](https://www.medrxiv.org/collection/neurology) (7600) * [Nursing](https://www.medrxiv.org/collection/nursing) (378) * [Nutrition](https://www.medrxiv.org/collection/nutrition) (1130) * [Obstetrics and Gynecology](https://www.medrxiv.org/collection/obstetrics-and-gynecology) (1296) * [Occupational and Environmental Health](https://www.medrxiv.org/collection/occupational-and-environmental-health) (1040) * [Oncology](https://www.medrxiv.org/collection/oncology) (3748) * [Ophthalmology](https://www.medrxiv.org/collection/ophthalmology) (1093) * [Orthopedics](https://www.medrxiv.org/collection/orthopedics) (410) * [Otolaryngology](https://www.medrxiv.org/collection/otolaryngology) (466) * [Pain Medicine](https://www.medrxiv.org/collection/pain-medicine) (502) * [Palliative Medicine](https://www.medrxiv.org/collection/palliative-medicine) (143) * [Pathology](https://www.medrxiv.org/collection/pathology) (721) * [Pediatrics](https://www.medrxiv.org/collection/pediatrics) (1859) * [Pharmacology and Therapeutics](https://www.medrxiv.org/collection/pharmacology-and-ther
## Related Clinical Research

- [Ion selectivity determines action-potential dynamics in modified Hodgkin–Huxley models](https://medichelpline.com/clinical-feed/biorxiv-5-ion-selectivity-as-a-biophysical-determinant-of-action-potential-dynamics.md)
- [Dendrite Control Theory Links Neuronal Shape to Voltage Control and Energy Trade-Offs](https://medichelpline.com/clinical-feed/biorxiv-1-dendrite-control-theory-a-unifying-framework-bridging-neuronal-morphology-and.md)
- [Bupropion Hydrochloride for Improving Recovery in Acute Ischaemic Stroke: BASE Trial Protocol](https://medichelpline.com/clinical-feed/bmj-open-4-protocol-for-base-a-multicentre-double-blind-randomised-controlled-trial-of.md)
- [Stakeholder preferences for long-acting injectables in tuberculosis treatment and prevention](https://medichelpline.com/clinical-feed/medrxiv-7-stakeholder-perspectives-and-preferences-for-long-acting-injectables-for.md)
- [Extended Treatment Duration and Recurrence in Cavitary Drug-Susceptible Pulmonary Tuberculosis](https://medichelpline.com/clinical-feed/plos-one-11-extended-treatment-duration-and-recurrence-in-successfully-treated-drug.md)

## Navigation
- [← Back to Neurology Feed](https://medichelpline.com/clinical-feed/neurology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.